What Is TB-500?
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide your body uses to repair damaged tissue. The version used in peptide therapy mimics the actin-binding region of the full molecule — the part that tells your cells to migrate, multiply, and rebuild.1
It's not FDA-approved for any medical use. TRT clinics compound it off-label for soft tissue injury recovery — muscle strains, tendonitis, ligament damage. You inject it subcutaneously, usually twice a week during a loading phase, then drop to once weekly for maintenance.
Most protocols stack TB-500 with BPC-157, another repair peptide. The idea is accelerated healing through complementary mechanisms. Evidence supporting this comes almost entirely from animal studies and clinical theory, not controlled human trials.2
You're buying it as a research chemical or compounded peptide. Quality varies. No regulatory oversight means you're trusting your clinic's sourcing and reconstitution practices.
TB-500 at a Glance
TB-500 is a synthetic peptide fragment designed to accelerate tissue repair by upregulating cellular migration and angiogenesis. TRT clinics use it off-label for soft tissue injuries, often stacked with BPC-157.
It's not FDA-approved, relies heavily on animal research, and carries unknown long-term risks.
- Mechanism: Binds actin to promote cell migration and blood vessel formation
- Dosing: 2.5-5 mg twice weekly (loading), then 2.5 mg weekly (maintenance)
- Safety: Minimal short-term side effects; contraindicated in active cancer
- Cost: $150-300/month; no insurance coverage
How TB-500 Works
TB-500 binds to actin, a protein that forms the scaffolding inside your cells. When you injure tissue, cells need to migrate to the wound site, reorganize their internal structure, and start rebuilding. Actin polymerization drives that process.2
The peptide upregulates this mechanism. In vitro studies show TB-500 boosts cell migration 2-3-fold at picogram concentrations — meaning tiny doses trigger measurable effects at the cellular level.3
Beyond cell movement, TB-500 promotes angiogenesis — the formation of new blood vessels that deliver oxygen and nutrients to healing tissue. It also modulates inflammatory signals. Animal models show faster wound contraction, increased collagen deposition, and enhanced keratinocyte migration in skin injuries.3
What the Research Shows
Most efficacy data comes from rodent studies. Rats treated with the parent molecule (thymosin beta-4) showed 11% faster wound contraction by day 7 compared to controls, with visible improvements in tissue architecture.3 Mouse cardiac studies demonstrated reactivation of embryonic progenitor cells in heart tissue, suggesting repair mechanisms beyond simple wound healing.4
Human data is limited to the full thymosin beta-4 molecule, not the TB-500 fragment. Phase 1 trials confirmed safety up to 1,260 mg over 14 days. A Phase 2 dry eye trial showed symptom improvement. A pilot cardiology study used TB4-primed stem cells post-heart attack, with some exercise capacity gains.5
Pharmacokinetics are poorly characterized. TB-500 undergoes C-terminal cleavage in human liver microsomes and plasma, but no studies report half-life, bioavailability, or excretion routes.6 The N-terminal acetylation protects the peptide from rapid degradation, extending its activity window beyond unmodified peptides.
Compared to full-length thymosin beta-4, TB-500 is cheaper to manufacture and easier to store. It targets the core actin-binding sequence but lacks TB4's additional domains that contribute to anti-apoptotic and broader immune-modulating effects.1
Actin Polymerization is the process by which actin protein molecules link together to form long filaments that reorganize a cell's internal structure, enabling cell movement and tissue repair during wound healing.
Angiogenesis is the formation of new blood vessels that grow into healing tissue to deliver oxygen and nutrients necessary for repair and regeneration.
Dosing & Administration
No standardized protocol exists — TB-500 has no FDA approval or official prescribing information. TRT clinics use off-label protocols adapted from research doses and anecdotal clinical experience.1
Most protocols follow a loading-maintenance pattern. You front-load with higher doses to saturate tissue, then taper to a lower maintenance frequency. Injections are subcutaneous — typically in the abdomen or thigh. Some practitioners inject near the injury site, though systemic distribution likely matters more than local concentration.
| Parameter | Standard Protocol | Clinical Notes |
|---|---|---|
| Loading Phase | 2.5-5 mg twice weekly, 4-6 weeks | Higher doses (5 mg) used for acute injuries; 2.5 mg for chronic issues |
| Maintenance Phase | 2.5 mg once weekly | Continue as long as symptom improvement persists; some stop after 8-12 weeks total |
| Injection Route | Subcutaneous | Intramuscular also used; no data comparing efficacy by route |
| Reconstitution | Bacteriostatic water, 2 mg/mL concentration | Store reconstituted vials refrigerated; use within 14 days |
| Monitoring | None required | No lab tests or imaging protocols established; clinical response drives decisions |
You'll receive the peptide as lyophilized powder. Reconstitute with bacteriostatic water per your clinic's instructions. Rotate injection sites to avoid local irritation. If you're stacking with BPC-157, some protocols inject both peptides simultaneously at different sites.
Side Effects & Safety
TB-500's safety profile comes primarily from thymosin beta-4 trials, which showed good tolerability up to 1,260 mg over two weeks.5 But that's the full molecule, not the synthetic fragment, and those were short-term studies in healthy volunteers.
Reported side effects are minimal. Most users experience mild injection site reactions — redness, slight swelling, occasional tenderness. Headaches occur in some patients, typically during the loading phase.
| Frequency | Side Effect | Severity |
|---|---|---|
| Common (>10%) | Injection site reactions (redness, swelling) | Mild |
| Occasional (1-10%) | Headache | Mild to Moderate |
| Occasional (1-10%) | Fatigue during loading phase | Mild |
| Unknown | Long-term cardiovascular or oncologic effects | Not established |
Pregnancy and breastfeeding are also contraindications due to lack of safety data. No studies assess fetal risk or transfer into breast milk.
Drug interactions haven't been studied. TB-500 doesn't interact with cytochrome P450 enzymes — it's metabolized via peptide cleavage, not hepatic pathways.6 Still, no formal interaction studies exist with common TRT medications, NSAIDs, or anticoagulants.
Quality control is the bigger safety concern. TB-500 is sold as a research chemical with no FDA oversight. Purity, sterility, and accurate dosing depend entirely on your supplier. Contamination and mislabeling are documented issues in the peptide market.
Cost & Access
TB-500 costs $150-300 per month depending on your protocol. Loading phases with higher doses push toward the upper end. Maintenance doses bring monthly costs down to $150-200.
No insurance coverage exists — it's not an FDA-approved drug. You're paying cash or using HSA/FSA funds if your clinic codes the visit appropriately.
Access routes are limited to compounding pharmacies or direct clinic sales. TRT clinics that offer peptide therapy typically source from specialized compounders. Some patients order from peptide research chemical suppliers online, but quality is unverifiable and legal status is murky.
Telehealth clinics prescribe TB-500 but ship restrictions vary by state. Some states ban compounded peptides without in-person evaluation. Others allow remote prescribing but require the patient to pick up from a local pharmacy.
If you're stacking TB-500 with BPC-157, expect total peptide costs around $300-500 monthly during loading, then $200-300 for maintenance. Most protocols run 8-12 weeks, so you're looking at $1,200-2,400 for a full treatment course.